| Overview |
| bsm-90194R |
| p38 MAPK Recombinant Antbody Kit (KD-Validated) |
| WB, FCM, IC |
| Knockdown Validated |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| A synthesized peptide derived from human p38 MAPK |
| 150-250/360 |
| Monoclonal |
| IgG |
| Lot dependent |
| Affinity Purified |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| -20 °C |
| Target |
| 1432 |
| Q16539 |
| MAPK14; Mitogen-Activated Protein Kinase 14; PRKM14; PRKM15; CSBP1; CSBP2; CSPB1; P38; Mitogen-Activated Protein Kinase P38 Alpha; MAX-Interacting Protein; CSAID-Binding Protein; MAP Kinase P38 Alpha; P38 MAP Kinase; MAP Kinase 14; EC 2.7.11.24; SAPK2A; Mxi2; CSBP; MXI2; Cytokine Suppressive Anti-Inflammatory Drug Binding Protein; Cytokine Suppressive Anti-Inflammatory Drug-Binding Protein; P38 Mitogen Activated Protein Kinase; Stress-Activated Protein Kinase 2A; Stress-Activated Protein Kinase 2a; MAP Kinase Mxi2; MAP Kinase MXI2; P38alpha Exip; EC 2.7.11; P38ALPHA; MAPK 14; SAPK2a; EXIP; RK |
| Cell Line: HT-1080 Knockdown technology: shRNA Knockdown |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IC |
1:1000 |
Powered by Bioz